Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2006, for eXegenics Inc. (Note: The input metadata references "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). The company has terminated all research and development activities and now operates as a holding company focused on redeploying residual assets. As of November 10, 2006, there were 16,991,101 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | As of Sep 30, 2006 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss (Attributable to Common) | $(168,000) | $(518,000) | N/A |
| Operating Expenses (G&A) | $280,000 | $640,000 | N/A |
| Other Income | $112,000 | $360,000 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $8,591,000 |
| Total Assets | N/A | N/A | $8,828,000 |
| Total Liabilities | N/A | N/A | $382,000 |
| Stockholders' Equity | N/A | N/A | $8,446,000 |
| Net Cash Used in Operating Activities | N/A | $(310,000) | N/A |
Note: All figures in thousands except per share data. The company reported no revenue for the periods presented.
Material Changes vs. Prior Period
- Operating Expenses: For the three months ended September 30, 2006, G&A expenses increased 44% to $280,000 from $194,000 in the prior year period. This was driven by a $120,000 increase in legal and accounting fees, including a $100,000 increase in reserves for ongoing litigation. Conversely, for the nine-month period, G&A expenses decreased 37% to $640,000 from $1,008,000, primarily due to reduced compensation and overhead costs following the termination of R&D activities.
- Other Income: Other income dropped significantly from $1,065,000 in the prior year quarter to $112,000. The 2005 figure included a $1,039,000 gain from the sale of Javelin Pharmaceuticals, Inc. stock, which did not recur in 2006. Interest income increased to $112,000 (from $26,000) due to higher interest rates and cash balances.
- Net Income/Loss: The company swung from a net profit of $871,000 in the prior year quarter to a net loss of $168,000 in the current quarter, largely due to the absence of the one-time investment gain in 2006.
Outlook, Risks, and Contingencies
- Strategic Direction: Management is focused on redeploying assets. On August 14, 2006, the company entered into a Stock Purchase Agreement with investors led by Dr. Phillip Frost to sell 51% of its common stock for approximately $8.6 million. Closing is expected in Q1 2007, subject to stockholder approval.
- Legal Proceedings: A jury ruled in favor of former employee Dr. Abdel Hakim Labidi, awarding $600,000 for conversion of biological materials. The company has recorded a $350,000 provision. The final liability is estimated between $350,000 and $750,000, pending court decisions on attorney fees and interest.
- Liquidity: The company holds approximately $8.6 million in cash. Net cash used in operating activities for the nine months was $310,000. Management believes current cash resources are sufficient to fund operations for the foreseeable future.
- Accounting Changes: The company adopted SFAS No. 123R (Share-Based Payment) on January 1, 2006, resulting in the recognition of share-based compensation expense ($3,000 for the quarter).
Investor Verification Checklist
- Transaction Closing: Verify the status of the proposed sale of 51% of common stock to the Dr. Phillip Frost-led group, including stockholder approval and closing date.
- Litigation Exposure: Monitor the final court ruling regarding attorney fees and interest in the Dr. Labidi case to confirm if the liability exceeds the $350,000 provision.
- Cash Burn Rate: Assess the sustainability of the $310,000 operating cash burn over the next 12 months relative to the $8.6 million cash balance.
- Preferred Stock Dividends: Note that preferred stock dividends ($238,000 for the nine months) were paid in additional shares, increasing the preferred share count and potentially diluting common equity upon conversion.